• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


One Ms really?

Tomorrow is promised to no one. Be prepared for any possible situation. Good luck to all. Remember, if you are severed from Novartis, do not apply to Biogen. Their problems are much greater than ours.
 




Tomorrow is promised to no one. Be prepared for any possible situation. Good luck to all. Remember, if you are severed from Novartis, do not apply to Biogen. Their problems are much greater than ours.

Novartis does the same crap. Over hire get the drug off the ground at launch. Then fire 25% after a year and a half.
 




















Hearing roll out will be next week or week after with division wide call first with leadership, then smaller calls for Kesimpta and S1P teams (East/West etc) minor geography shifts to larger territories for new merged teams (S1P/kesimpta specialist) but districts may shrink for ABL’s. Could be in a two rep territory depending on size or a 1 rep with virtual overlay. They really wanted this to be based on business potential and maximizing impact. Overall the reduction could be 10-15% of both teams headcount wise but since they were not backfilling positions in anticipation and the creation of new roles the actual headcount loss could be minimal. As painful as this may be, it is the right business move as the MS division is too bloated and has to slim things down to be better aligned as portfolio selling starts.